Remove 2018 Remove Drug Pricing Remove Pharmaceutical Companies
article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

article thumbnail

Pharmacy benefit management demystified: How PBMs influence prescription drug pricing

HealthPartners

Ultimately, this insight can help ensure your company and your employees are getting the greatest value from your pharmacy benefits plan. Understanding pharmacy benefit management and drug pricing The U.S. prescription drug supply chain is extraordinarily complex. To better understand it, see the below diagram.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceutical companies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets. appeared first on Express Pharma.

article thumbnail

Haven: The strategy that didn’t fix healthcare

pharmaphorum

Few details about Haven emerged after the new venture was announced to the public in January 2018 and the Haven brand name did not appear until about a year later. CVS Health, Walmart, Cardinal Health and Express Scripts were among those affected. He told his guests, “We are not happy with healthcare costs and want to help.”

article thumbnail

Sandoz spin-off continues Novartis’ focus on innovation; $22bn purchase rumoured

Pharmaceutical Technology

Sandoz has faced and may in the future face strong competition from other generic and biosimilar pharmaceutical companies, which aggressively compete for market share, including through significant price competition. The company had revenues of $9.6bn both in 2020 and last year. The site employs around 250 people.

article thumbnail

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

pharmaphorum

Jesse Mendelsohn explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying that if pharmaceutical companies are not profitable, they will not survive. The truth about rising drug prices is more nuanced and merits exploration. The Big Misconception.